785TiPPhase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer. (23rd October 2018) - Kato, K; Shah, M A; Enzinger, P C; Bennouna, J; Shen, L; Adenis, A; Sun, J-M; Cho, B C; Ozguroglu, M; Kojima, T; Kostorov, V; Hierro, C; et al.